About the Author(s)


Catherine Farmer symbol
Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

Elsa du Toit symbol
Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

Panorama Healthcare Psychiatry, Cape Town, South Africa

Ulla Botha symbol
Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

Dana Niehaus symbol
Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

Liezl Koen Email symbol
Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

Citation


Farmer C, Du Toit E, Botha U, Niehaus D, Koen L. Psychotropic prescribing patterns during pregnancy in two South African mental health clinics. J Coll Med S Afr. 2025;3(1), a188. https://doi.org/10.4102/jcmsa.v3i1.188

Original Research

Psychotropic prescribing patterns during pregnancy in two South African mental health clinics

Catherine Farmer, Elsa du Toit, Ulla Botha, Dana Niehaus, Liezl Koen

Received: 30 Jan. 2025; Accepted: 12 Sept. 2025; Published: 17 Oct. 2025

Copyright: © 2025. The Author(s). Licensee: AOSIS.
This work is licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license (https://creativecommons.org/licenses/by/4.0/).

Abstract

Background: Given that there is a significant burden of mental illness during pregnancy, psychotropic polypharmacy during this period is commonly found in clinical practice. In South Africa, however, there is a paucity of data on the use of psychotropics during pregnancy.

Methods: This was a retrospective descriptive study of 303 pregnant women attending two specialised maternal mental health clinics from presentation to six weeks postpartum. Demographic data, psychiatric history, medical comorbidity, pregnancy-related, and prescription data were collected and tabulated at treatment-as-usual visits. Polypharmacy prevalence was defined as the prescription of two or more psychotropics for at least 90 days.

Results: A majority of the study group was diagnosed with major depressive disorder (n = 161, 53.1%), and non-tricyclic antidepressants were the most prescribed medication class (n = 195, 64.4%). One-third of the participants received prescriptions in all three trimesters. Polypharmacy criteria were met in 18.8% (n = 57) of the sample population.

Conclusion: The prescription patterns in the study sample appeared to be in line with current international protocols. Prescribing psychotropics during pregnancy remains challenging because of the need to weigh up the potential risks of medication-related effects on the mother and baby against those of discontinuing treatment.

Contribution: This study may raise awareness and assist medical professionals regarding the rational use of psychotropic medication during pregnancy.

Keywords: psychotropics; pregnancy; polypharmacy; maternal mental health; prescription patterns; psychiatric diagnosis.

Introduction

Pregnancy is associated with a significantly increased risk for new onset or relapse of mental illness, both in high and low- to middle-income countries (LMICs).1,2 In Northern Ireland, Mongan et al.3 reported a prevalence of 18.9% for self-reported mental disorders during pregnancy. In LMICs, this prevalence appears to be higher with Faisal-Cury et al.4 reporting 20.2% in Sao Paulo, Brazil and Woldetadik et al.5 reporting 35.8% in South-East Ethiopia. In South Africa, Zar et al.6 conducted a study in pregnant women of black African and mixed ancestry, attending two public health facilities in the Drakenstein area in Paarl, Western Cape province. Pregnant women were enrolled in their second trimester and followed through childbirth. The study reported that 24% of pregnant women scored above the threshold for depression using the Edinburgh Postnatal Depression Scale (EPDS) and 20% scored above the threshold for psychological distress using the Self-Reporting Questionnaire (SRQ-20). Hartley et al.7 also reported depressed mood (EPDS score-based) in 39% of mothers in a community-based, cluster-randomised controlled trial in Khayelitsha and Mfuleni in Cape Town, South Africa.

Failure to treat mental illness during pregnancy could result in negative outcomes for both the mother and the baby. A systematic review found that maternal mental illness increased the risk for infant mortality and/or stillbirth,8 and that the risk of having a preterm birth or delivering a baby with low birth weight was higher for women with untreated depression.9 Further, the impact of maternal mental illness during pregnancy may also extend to later developmental periods of the baby, where adolescents who were exposed to maternal depression in utero and during the postnatal period were reported to have a 4.7 times greater risk of developing depression compared to unexposed babies.10 For mothers, the strongest determinant of postnatal depression is antenatal depression.11

Potential risks of psychotropic medication use during pregnancy can be divided into two broad categories.12 Firstly, risks to the developing child, including teratogenicity, withdrawal and long-term behavioural effects and secondly, pregnancy complications that could affect both the mother and the baby, including spontaneous abortion, pre-eclampsia and postpartum haemorrhage. The management of psychotropic medications in women planning pregnancy and those already pregnant requires careful risk-benefit assessment, as all psychotropic medications cross the placenta and are present in amniotic fluid.13,14 Current guidelines15,16,17,18 emphasise that the safest and most effective maternal dose should be prescribed when the benefits of treatment outweigh potential risks. Administering higher doses of a single pharmacological agent is generally preferable to polypharmacy. Additionally, the selection of drugs characterised by limited metabolite formation, high protein-binding affinity and a low potential for drug–drug interactions is recommended. Pre-conception counselling is emphasised as a critical component of care, with National Institute for Health and Care Excellence (NICE) guidelines specifically addressing the recognition, assessment and treatment of mental health problems in women planning pregnancy.19 The South African Department of Health’s Standard Treatment Guidelines and Essential Medicines List for South Africa also provide prescribing guidelines for women of childbearing age and during pregnancy.17,18

For antidepressants, selective serotonin reuptake inhibitors remain first-line treatments and are considered safe to use during pregnancy when treatment is needed, although paroxetine should be avoided across all trimesters and benzodiazepines should be avoided during the first trimester because of teratogenic risks and potential neonatal withdrawal symptoms.20,21,22,23 Regarding antipsychotics, several recent reviews have shown that the majority of studies have found antipsychotic use during pregnancy to be safe, with risperidone being a possible exception.24,25 It is thus recommended that women who need to take antipsychotics continue to do so during pregnancy. While no currently available antidepressants or antipsychotics are contraindicated during pregnancy, healthcare providers should consider the risks and benefits of the antipsychotics and antidepressants prescribed.24,26 Mood stabilisers (i.e. some antiseizure medications are used as mood stabilisers for the management of bipolar disorder), such as lamotrigine and lithium, are considered acceptable options with appropriate risk-benefit analysis,27,28 while the use of lithium during the first trimester has been shown to increase the risk for major malformations.29 The use of other mood stabilisers, especially sodium valproate and carbamazepine, should be avoided because of the high risk of major malformations and long-term developmental defects.30,31,32

Discontinuation of medication in pregnant women diagnosed with a serious mental illness could pose significant risks. Seki et al.33 reported a relapse rate of 16.7% in a group of pregnant women with schizophrenia who remained on treatment versus 90.0% in the discontinuation group. This increased risk seems to cross diagnostic borders, where women with bipolar disorder who discontinued their medication versus those who continued mood stabiliser treatment had a two-fold increased recurrence risk, a shorter time to recurrence and spent more time being ill during their pregnancy.34 According to Wesseloo et al.,35 patients with a diagnosis of bipolar mood disorder not receiving prophylactic medication during pregnancy had significantly higher rates of relapse during the postpartum period compared to those on prophylactic treatment (66% [95% confidence interval: 57–75] vs. 23% [95% confidence interval: 14–37]).

The ideal approach to managing pregnant patients with mental illness is through pregnancy planning and individualising treatments based on the risk profile of the patient.36 However, the prevalence of unintended or unplanned pregnancy in sub-Saharan Africa averages about 29%.37 In South Africa, Du Toit et al.38 reported that more than half of the patients presented with an unplanned pregnancy. It therefore becomes necessary to focus on a pragmatic risk-based management plan where the foetal risks of continued exposure to potentially dangerous drugs should be carefully weighed up against the risk of relapse for the mother if medication were to be discontinued.36,39

There is a paucity of data on the use of psychotropic medication during pregnancy in South African women suffering from a mental illness. Using data from a previous maternal mental health outcomes umbrella study,38 this study aimed to describe the psychotropic medication prescription patterns and prevalence of polypharmacy during pregnancy at specialist-level maternal mental health clinics in the Western Cape province of South Africa.

Research methods and design

Study design

This was a descriptive, retrospective cohort study of psychotropic medication prescriptions in 303 pregnant women attending two secondary-level specialist maternal mental health clinics in Cape Town, South Africa. Participants were included from conception until six weeks postpartum.

Study setting

The umbrella study38 was conducted at two specialised maternal mental health clinics in Cape Town, South Africa – one private sector (Sophia Perinatal Psychiatry Clinic) and one state sector (Stikland Maternal Mental Health Outpatient Clinic). Stikland Hospital is a public tertiary-level stand-alone psychiatric hospital operating in the Northern and Tygerberg Districts of Cape Town. The hospital provides all levels of psychiatric care to a part of the Tygerberg East metro region, as well as to the West Coast and Winelands rural regions. The Sofia Perinatal Psychiatry Clinic, a division of the Panorama Healthcare Psychiatry, is a privately owned clinic operating in the Northern District of Cape Town. Both clinics provide outpatient perinatal mental healthcare. Patients accessing care at the private Sofia clinic typically earn more than those accessing care from the state clinic, as they require either medical insurance coverage or sufficient personal finances to pay for private healthcare services. Patients were mostly referred to the Stikland and Sophia clinics by general physicians working in primary healthcare, but patients seen at the Sophia clinic could also be self-referred.

Study sample

Participants included in this study formed part of a larger study that aimed to describe the maternal and foetal outcomes of pregnancy in women with mental illness in a developing country and to identify risk factors for adverse pregnancy outcomes.38 The larger study used convenience sampling for participant recruitment, through enrolling (after receiving voluntary written, informed consent) participants who accessed mental healthcare services at one of the specialist clinics. Females (aged 18–45 years) with a primary Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) diagnosis of severe psychiatric illness, including psychotic, mood and anxiety disorders, were included. A recent general household survey by Statistics South Africa in 201840 determined that 71.5% of South Africans had access to public healthcare, while 27.1% had access to private healthcare. The umbrella study participants were recruited in a ratio of 3:2 from the state and private clinics, respectively. The ratio of recruitment was chosen to give a true-to-life picture of the current pattern of referral to specialist psychiatric services.

Data collection

Data were collected during the four care-as-usual visits (an initial evaluation followed by one visit per trimester and six weeks postpartum) and captured onto an Excel spreadsheet (umbrella study). The current study expanded the database by capturing detailed information on the psychotropic medication prescriptions using the existing case report forms and clinical case notes (including prescription charts).

Demographic data, psychiatric history, medical comorbid illnesses, as well as pregnancy-related data were tabulated. Medication received by the participants was divided into 12 categories (Table 1). Because of their dissimilar side effect profiles, different classes of antipsychotics, antidepressants and mood stabilisers were analysed separately. Polypharmacy was defined as the use of two or more psychotropic medication prescriptions for at least 90 days, as recommended in the validation study by Leckman-Westin et al.41 and used in a similar study by Broeks et al.42 If there was a medication change, then this was seen as a new polypharmacy episode.

TABLE 1: Types of medications received by study participants.
Data analysis

Data were analysed using IBM SPSS Statistics, Version 28 ([computer program]. Armonk, NY: IBM Corporation; 2021). Continuous variables were summarised as mean and standard deviation or median and interquartile ranges, while nominal variables were summarised as counts and percentages. Because this was a descriptive study, no further statistical methods were employed.

Ethical considerations

Ethical clearance to conduct this study was obtained from the Health Research Ethics Committee of Stellenbosch University (Umbrella Study HREC reference number N12/10/071; current Study HREC reference number S21/04/063) and the National Department of Health. Stringent protocols were put in place to ensure the safety and confidentiality of patient records during the data collection phase, and all collected data were anonymised by the removal of direct identifiers. A waiver of informed consent was granted, given the retrospective nature of the study. This study was conducted in accordance with the Declaration of Helsinki.43

Results

Demographic variables

The study sample comprised 303 participants with a mean age of 31.0 years (s.d. = 5.51) and a mean paternal age of 34.8 years (s.d. = 6.62). Participants were mostly married (n = 178, 58.7%), 48.8% (n = 148) were employed, 39.9% (n = 121) had a tertiary-level education, and Afrikaans was the most commonly spoken language (n = 212, 70.0%) (Table 2).

TABLE 2: Demographic characteristics of the study sample (N = 303).
Pregnancy-related variables

The study participants’ initial visit to the treatment facilities spanned all three trimesters, where 43.6% (n = 132) presented in their first trimester, 38.3% (n = 116) presented in their second trimester and 16.8% (n = 51) presented in their third trimester. The mean gestational age at the initial visit was 17.0 weeks (s.d. = 9.14, range = 36). Gravidity ranged from one (n = 80, 26.4%) to eight (n = 1, 0.3%), with the majority having had two pregnancies (n = 93, 30.7%), while parity ranged from zero (n = 112, 37.0%) to four (n = 6, 2.0%), with the majority having had given birth to one foetus with a gestational age of 24 weeks (n = 115, 38.0%). Most participants had not miscarried (n = 213, 70.3%) or terminated their pregnancies (n = 266, 87.8%). More than half reported that their pregnancies were planned (n = 159, 52.5%), 69.3% (n = 210) indicated that they were anticipating a normal vertex delivery and 80.2% (n = 243) planned to breastfeed.

Medical comorbidity

Almost a quarter (n = 73, 24.1%) of participants reported comorbid medical illnesses, with endocrine (n = 15, 5.0%) and cardiac (n = 15, 5.0%) disorders being the most common (Table 3). Injuries and acute infections were not included in this analysis.

TABLE 3: The prevalence of medical disorders (system-based) in the study participants (N = 303).
Psychiatric disorders

Major depressive disorder was the most prevalent (n = 161, 53.1%), followed by bipolar I disorder (n = 41, 13.5%) and schizophrenia (n = 37, 12.2%) (Table 4). Most participants had one psychiatric diagnosis (n = 217, 71.6%). Almost half of the participants had a psychiatric admission (n = 138, 46.0%), with a median of one psychiatric admission (IQR = 1–2, range = 1–9). The mean length of psychiatric admission was 13.01 days (s.d. = 27.95) for those who were admitted. The mean number of suicide attempts was 0.50 (s.d. = 0.76).

TABLE 4: Participants’ psychiatric disorders according to diagnostic and statistical manual of mental disorders, fourth edition, text revision.
Substance use history during current pregnancy

Most participants reported no alcohol (n = 249, 82.1%) or caffeine (n = 173, 57.1%) use (Table 5). Participants reported substance use as follows: alcohol use (n = 51, 16.8%), methamphetamine use (n = 18, 5.9%), cannabis use (n = 12, 4.0%) and tobacco use (n = 105, 34.7%). Of those using tobacco cigarettes, on average, 3.6 (s.d. = 4.26) cigarettes were smoked per day.

TABLE 5: Participants’ substance use history during their current pregnancy.
Medication prescription patterns by trimester and drug class

The majority of participants (n = 289, 95.4%) were on prescribed psychotropics at any point during their pregnancy (Table 6). Of those prescribed psychotropics, just over a third of participants (n = 103, 34.0%) were prescribed three psychotropics at any point during their pregnancy. Approximately 20% of participants were prescribed five or more psychotropics during their pregnancy, with one participant prescribed 11 psychotropics throughout their pregnancy. The number of participants on psychotropics decreased by trimester, with 80.9% (n = 245) prescribed psychotropics during the first trimester compared to 77.2% (n = 2.4) and 66.7% (n = 202) for the second and third trimesters, respectively. Per trimester, approximately half of the participants were prescribed one psychotropic. For the total sample, 953 psychotropic items were prescribed.

TABLE 6: Number of participants who had psychotropic medication prescriptions by trimester.

For the specific psychotropics, two-thirds of the participants were prescribed an antidepressant during pregnancy, of which 64.4% (n = 195) were prescribed a non-tricyclic and 2% (n = 6) a tricyclic antidepressant, where the non-tricyclic antidepressants were prescribed during all trimesters (Table 7). For antipsychotic medications, 13.5% (n = 41) were prescribed typical and 29.0% (n = 88) were prescribed atypical antipsychotic medications during their pregnancy. Atypical antipsychotics were prescribed during all trimesters. Out of the mood stabilisers, 7.3% (n = 22) were prescribed sodium valproate, 8.3% (n = 25) were prescribed lamotrigine, 1.7% (n = 5) were prescribed carbamazepine, 0.3% (n = 1) were prescribed topiramate and 5.3% (n = 16) were prescribed lithium during their pregnancies. Furthermore, all sodium valproate, carbamazepine and topiramate were prescribed during the first trimester. Gabapentin was prescribed for one patient during the second trimester of pregnancy. Thirty-four participants (11.2%) were prescribed sedatives during pregnancy. The 19 participants (6.3%) who received other medication (beta-blockers, antihistamine medication and anticholinergic medication, which may have some effect on psychiatric disorders) had it prescribed during the first trimester. Fifty-seven participants (18.8%) met the criteria for psychotropic polypharmacy, which was defined as the use of more than one psychotropic drug for at least 90 days (data not shown).

TABLE 7: Number of participants who had psychotropic medication prescriptions by trimester and drug class.

Discussion

This study sought to describe the psychotropic medication prescription patterns and rates of polypharmacy during pregnancy in patients attending two maternal mental health clinics in Cape Town, South Africa. Overall, antidepressants were the most prescribed class of medication, and just under a fifth of the participants met the criteria for polypharmacy during pregnancy.

In our study, the antidepressant prescription rate aligns with major depressive disorder being the most prevalent diagnosis in our sample. Evidence for the risk of cardiac abnormalities in the offspring of women using antidepressants during pregnancy is mixed. A study by Knudsen et al.,44 investigating all registered pregnancies (n = 72 280) in Funen, Denmark, from 1995 to 2008, reported a fourfold increased risk for cardiac abnormalities during the first trimester. However, other studies have concluded that the offspring of patients using selective serotonin reuptake inhibitors (SSRIs) did not show an increased risk of major cardiac abnormalities.45,46 With regard to tricyclic antidepressants, Gentile47 noted an increased risk for congenital malformations with tricyclic antidepressant exposure during the first trimester. It was also noted that when tricyclic antidepressants were used late in pregnancy, the maternal risks included a possible increased risk of pre-eclampsia and a mild popliteal artery entrapment syndrome. The low usage of this type of antidepressant in our sample is in keeping with research data on the safety of these drugs.

Antipsychotic medications were the second most common drug prescribed in our patient sample. In a study conducted in the USA, based on the nationwide Medicaid Analytic Extract database (01 January 2000 to 31 December 2010), the use of both atypical and typical antipsychotics was not significantly associated with an increased risk for congenital malformations overall or cardiac malformations in particular.48 The overall use of second-generation antipsychotics during pregnancy has been shown to increase the risk of gestational diabetes, but this was not limited to a specific trimester.49 Some studies have shown that the use of antipsychotics during a pregnancy may increase the risk of maternal diabetes and extrapyramidal symptoms in the mother and malformations, extrapyramidal symptoms and autonomic instability in the infants.50 Clinicians did not provide reasons for discontinuation, although it can be speculated that concerns for the well-being of the foetus might have played a role.

Of the mood stabilisers prescribed, current guidance recommends that the use of sodium valproate should be avoided in women of childbearing age because of potential risks of neural tube birth defects and developmental disorders in children who are exposed to it during pregnancy.32,51,52,53 Furthermore, women of childbearing age who are currently prescribed sodium valproate should be placed on effective contraception, without stopping or interruption, while on the psychotropic. Important to note that the number of patients receiving sodium valproate in the first trimester was higher than in the second and third trimesters. This may be linked to more than 50% of pregnancies being unplanned, in which case patients often present late in the first trimester on medication that had been prescribed pre-conception. Future studies should explore whether these cases were related to failed contraception or poor contraceptive counselling. Previous studies have also shown that, contrary to national and international guidance on not prescribing sodium valproate to women of childbearing age, this psychotropic continues to be prescribed and that proper counselling is not always provided in South Africa.54,55,56

Lamotrigine has been shown to have a similar risk for congenital abnormalities in the offspring of women using this drug compared to women not using anticonvulsant medication during pregnancy; thus, it appears to have a low to minimal risk for foetal structural defects.57 Tomson et al.57 also concluded that carbamazepine exposure at conception was associated with a risk of major congenital abnormalities, and as such, the first trimester is considered a critical one. Pregnancy planning in conjunction with psychiatric counselling could prevent mothers from conferring risk to their offspring by changing carbamazepine to a safer drug.

The use of topiramate during the first trimester in a study by Hernandez-Diaz et al.58 resulted in an increased risk of cleft lip. Studies have also shown an increased risk for autism spectrum disorders and intellectual disability in children with prenatal exposure to topiramate.59,60 In our sample, only one patient was prescribed topiramate (diagnosed with anxiety, depression and migraines) and only in the third trimester. The risk of Ebstein’s anomaly has been associated with lithium use in the first trimester.61 Given the physiological changes in body water distribution during pregnancy, more regular monitoring of lithium levels during pregnancy is recommended.28 In keeping with safety data, lamotrigine was the mood stabiliser of choice in our sample.

Ogawa et al.62 found an increased risk of preterm delivery in participants receiving benzodiazepines irrespective of trimester. Given the dependence-producing potential of these drugs, sudden discontinuation is not advisable. Pregnancy-safe medication options and psychotherapy would be more suitable, depending on the patient’s individual circumstances and needs.

The rate of polypharmacy in this study is in line with a similar Australian study by Galbally et al.63 (N = 535), who found that pregnant women with bipolar mood disorder were twice as likely, compared to all other pregnant women (with a schizophrenia or a non-psychotic severe mental illness primary diagnosis) in the study, to have a prescription of two or more psychotropic agents at any point during their pregnancy. However, Broeks et al.,42 using the same definition for polypharmacy as in our study, reported an incidence of polypharmacy double that of our sample, based on data from the Danish National Prescription Registry and investigating psychotropic use among women with bipolar disorder from 12 months pre-conception to 12 months postpartum. Polypharmacy could conceivably increase the risks of psychotropic use during pregnancy via an additive effect of the various drugs or through drug–drug interactions.64 It was noted by Galbally et al.63 that the real-life prescribing pattern of psychotropic medication is not as well researched in comparison with studies that research the effects of a specific medication or medication class on foetal outcomes. The analysis of prescription practice adds a dimension of understanding and can help to develop future studies on psychotropic medication effects during pregnancy.

Ultimately, the potential risks associated with untreated mental illness during pregnancy need to be balanced against the risks of foetal exposure to psychotropics. To assist in determining the safety of general medication use in pregnancy, the US Food and Drug Administration published a ‘Pregnancy and Lactation Labelling Rule’ in 2014.65 This is a narrative labelling system that focuses on the pregnancy phase (information obtained from a pregnancy exposure registry), lactation (effect of the drug during breastfeeding) and men and women of reproductive potential (pregnancy testing, contraception and infertility). Psychiatric medication manufacturers are required to review available literature to compile a risk summary for each drug and indicate the limitations of the evidence.66 However, compiling a risk statement can be challenging if there is limited data or poor-quality evidence available on the medication. Within this uncertainty, local guidelines, such as the South Africa Department of Health – Standard Treatment Guidelines, can assist health professionals in guiding mental healthcare users and their partners through the treatment options, and health professionals are encouraged to regularly review existing local guidelines on the use of medication in pregnancy.17,18

Limitations

This study described the pattern of medication prescription only; it can therefore not be certain whether the participants used the medication or maintained adherence. The dose of the psychotropic medication was also not indicated, which can have foetal and maternal adverse effects. Some of the medication groupings used were broad, for example, antipsychotic medication; it is possible that nuanced contributions by drugs with dissimilar mechanisms of action are not appropriately highlighted. It was also not possible to explore the context of first trimester prescribing patterns, specifically related to sodium valproate. It would be important to know if patients had been counselled regarding contraception and teratogenic risks associated with pregnancy before starting the medication. Within the antipsychotic group, different medications have different risks to the foetus. Further research is required to determine the long-term effects of exposure to psychotropic medication during pregnancy. The study did not have access to detailed clinical notes from the initial prescribers; therefore, it is unclear whether psychotropic medications were prescribed as a well-motivated exception with the patients’ informed consent (as required) or if these patterns are because of prescribing ignorance, late presentation or drug availability. Of note is that valproate prescription in the first trimester is often a result of patients who have been on valproate before conception and were either not aware that they were pregnant or were not fully informed of the risk.

Conclusion

In conclusion, the prescription pattern in the study sample appears to be mostly in line with current protocols. The Maudsley Prescribing Guidelines in Psychiatry36 recommend that if a woman is planning a pregnancy, one can consider stopping medication if she is at low risk of relapse. If a woman taking psychotropic medication finds out that she is pregnant, the recommendation is that she continue treatment and not switch treatment. Prescribing psychotropic drugs during pregnancy is challenging because of the need to weigh up the potential risks of drug-related effects on both the mother and child against those of discontinuing treatment. A structured approach to patient care and the use of available resources about the effects of individual drugs can aid the clinician who is confronted with such cases.

Acknowledgements

This article includes content that overlaps with research originally conducted as part of Catherine Farmer’s MMed research assignment titled ‘Psychotropic medication prescribing patterns during pregnancy in two South African Maternal Mental Health clinics’, submitted to the Faculty of Medicine and Health Sciences, Stellenbosch University in 2022.67 The thesis was supervised by Dana Niehaus and Liezl Koen. Portions of the data, analysis and/or discussion have been revised, updated and adapted for journal publication. The original thesis is publicly available at: https://scholar.sun.ac.za/handle/10019.1/129091. The authors affirm that this submission complies with ethical standards for secondary publication and appropriate acknowledgement has been made of the original work. We would like to thank Dr Muneeb Salie for writing and technical assistance.

Competing interests

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.

Authors’ contributions

E.d.T., D.N. and L.K. conceived the study. E.d.T., U.B., D.N. and L.K. designed the methodology. C.F. and D.N. performed the investigation with D.N. conducting the analysis. C.F. wrote the original draft of the manuscript and all authors reviewed and approved the final manuscript.

Funding information

The authors received no financial support for the research, authorship and/or publication of this article.

Data availability

The data that support the findings of this study are available from the corresponding author, L.K., upon reasonable request.

Disclaimer

The views and opinions expressed in this article are those of the authors and are the product of professional research. They do not necessarily reflect the official policy or position of any affiliated institution, funder, agency, or that of the publisher. The authors are responsible for this article’s results, findings and content.

References

  1. Tamiru D, Misgana T, Tariku M, et al. Prevalence and associated factors of common mental disorders among pregnant mothers in rural Eastern Ethiopia. Front Psychiatry. 2022;13:843984. https://doi.org/10.3389/fpsyt.2022.843984
  2. Gelaye B, Rondon MB, Araya R, et al. Epidemiology of maternal depression, risk factors, and child outcomes in low-income and middle-income countries. Lancet Psychiatry 2016;3(10):973–982. https://doi.org/10.1016/S2215-0366(16)30284-X
  3. Mongan D, Lynch J, Hanna D, et al. Prevalence of self-reported mental disorders in pregnancy and associations with adverse neonatal outcomes: A population-based cross-sectional study. BMC Pregnancy Childbirth. 2019;19(1):412. https://doi.org/10.1186/s12884-019-2572-4
  4. Faisal-Cury A, Menezes P, Araya R, et al. Common mental disorders during pregnancy: Prevalence and associated factors among low-income women in São Paulo, Brazil: Depression and anxiety during pregnancy. Arch Womens Ment Health. 2009;12(5):335–343. https://doi.org/10.1007/s00737-009-0081-6
  5. Woldetsadik AM, Ayele AN, Roba AE, et al. Prevalence of common mental disorder and associated factors among pregnant women in South-East Ethiopia, 2017: A community based cross-sectional study. Reprod Health. 2019;16(1):173. https://doi.org/10.1186/s12978-019-0834-2
  6. Zar HJ, Pellowski JA, Cohen S, et al. Maternal health and birth outcomes in a South African birth cohort study. PLoS One. 2019;14(11):e0222399. https://doi.org/10.1371/journal.pone.0222399
  7. Hartley M, Tomlinson M, Greco E, et al. Depressed mood in pregnancy: Prevalence and correlates in two Cape Town peri-urban settlements. Reprod Health. 2011;8:9. https://doi.org/10.1186/1742-4755-8-9
  8. Adane AA, Bailey HD, Morgan VA, et al. The impact of maternal prenatal mental health disorders on stillbirth and infant mortality: A systematic review and meta-analysis. Arch Womens Ment Health. 2021;24(4):543–555. https://doi.org/10.1007/s00737-020-01099-9
  9. Jarde A, Morais M, Kingston D, et al. Neonatal outcomes in women with untreated antenatal depression compared with women without depression: A systematic review and meta-analysis. JAMA Psychiatry. 2016;73(8):826–837. https://doi.org/10.1001/jamapsychiatry.2016.0934
  10. Pawlby S, Hay DF, Sharp D, et al. Antenatal depression predicts depression in adolescent offspring: Prospective longitudinal community-based study. J Affect Disord. 2009;113(3):236–243. https://doi.org/10.1016/j.jad.2008.05.018
  11. Pampaka D, Papatheodorou SI, AlSeaidan M, et al. Postnatal depressive symptoms in women with and without antenatal depressive symptoms: Results from a prospective cohort study. Arch Womens Ment Health. 2019;22(1):93–103. https://doi.org/10.1007/s00737-018-0880-8
  12. Nordeng H, Van Gelder MMHJ, Spigset O, et al. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: Results from the Norwegian mother and child cohort study. J Clin Psychopharmacol. 2012;32(2):186–194. https://doi.org/10.1097/JCP.0b013e3182490eaf
  13. ACOG Committee on Practice Bulletins – Obstetrics. ACOG practice bulletin no. 92: Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111(4):1001–1020. https://doi.org/10.1097/AOG.0b013e31816fd910
  14. Creeley CE, Denton LK. Use of prescribed psychotropics during pregnancy: A systematic review of pregnancy, neonatal, and childhood outcomes. Brain Sci. 2019;9(9):235. https://doi.org/10.3390/brainsci9090235
  15. Vickery PB. Concepts for selection and utilization of psychiatric medications in pregnancy. Ment Health Clin. 2023;13(6):255–267. https://doi.org/10.9740/mhc.2023.12.255
  16. Costa B, Vale N. Advances in psychotropic treatment for pregnant women: Efficacy, adverse outcomes, and therapeutic monitoring. J Clin Med. 2024;13(15): 4398. https://doi.org/10.3390/jcm13154398
  17. Department of Health. Standard treatment guidelines and essential medicines list for South Africa – Hospital level, adults. 2024 ed. Pretoria; 2024.
  18. Robertson LJ, Dawood H, Leong TD. Management of bipolar disorder in South Africa: National Department of Health essential medicine selection and treatment algorithms. S Afr J Public Health. 2023;7(1):e530. https://doi.org/10.7196/SAJPH.2023.v7.i1.530
  19. National Institute for Health and Care Excellence (NICE). Recommendations | Antenatal and postnatal mental health: Clinical management and service guidance | Guidance [homepage on the Internet]. NICE. 2014 [cited 07 August 2025]. Available from: https://www.nice.org.uk/guidance/cg192/chapter/recommendations
  20. Susser LC, Sansone SA, Hermann AD. Selective serotonin reuptake inhibitors for depression in pregnancy. Am J Obstet Gynecol. 2016;215(6):722–730. https://doi.org/10.1016/j.ajog.2016.07.011
  21. Chu A, Wadhwa R. Selective serotonin reuptake inhibitors [homepage on the Internet]. 2023 [14 August 2025]. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK554406/
  22. Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea. PLoS Med 2022;19(3):e1003945. https://doi.org/10.1371/journal.pmed.1003945
  23. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002;53(1):39–49. https://doi.org/10.1176/appi.ps.53.1.39
  24. Betcher HK, Montiel C, Clark CT. Use of antipsychotic drugs during pregnancy. Curr Treat Options Psychiatry. 2019;6(1):17–31. https://doi.org/10.1007/s40501-019-0165-5
  25. Bruno C, Cesta CE, Hjellvik V, et al. Antipsychotic use during pregnancy and risk of specific neurodevelopmental disorders and learning difficulties in children: A multinational cohort study. EClinicalMedicine. 2024;70:102531. https://doi.org/10.1016/j.eclinm.2024.102531
  26. Payne JL, Meltzer-Brody S. Antidepressant use during pregnancy: Current controversies and treatment strategies. Clin Obstet Gynecol. 2009;52(3):469–482. https://doi.org/10.1097/GRF.0b013e3181b52e20
  27. Albertini E, Ernst CL, Tamaroff RS. Psychopharmacological decision making in bipolar disorder during pregnancy and lactation: A case-by-case approach to using current evidence. Focus: J Life Long Learn Psychiatry. 2019;17(3):258. https://doi.org/10.1176/appi.focus.20190007
  28. Wesseloo R, Wierdsma AI, Van Kamp IL, et al. Lithium dosing strategies during pregnancy and the postpartum period. Br J Psychiatry. 2017;211(1):31–36. https://doi.org/10.1192/bjp.bp.116.192799
  29. Munk-Olsen T, Liu X, Viktorin A, et al. Maternal and infant outcomes associated with lithium use in pregnancy: An international collaborative meta-analysis of six cohort studies. Lancet Psychiatry. 2018;5(8):644–652. https://doi.org/10.1016/S2215-0366(18)30180-9
  30. Grover S, Avasthi A. Mood stabilizers in pregnancy and lactation. Indian J Psychiatry. 2015;57(suppl 2):S308. https://doi.org/10.4103/0019-5545.161498
  31. Battino D, Tomson T, Bonizzoni E, et al. Risk of major congenital malformations and exposure to antiseizure medication monotherapy. JAMA Neurol. 2024;81(5):481–489. https://doi.org/10.1001/jamaneurol.2024.0258
  32. Madley-Dowd P, Ahlqvist VH, Forbes H, et al. Antiseizure medication use during pregnancy and children’s neurodevelopmental outcomes. Nat Commun. 2024;15(1):1–11. https://doi.org/10.1038/s41467-024-53813-1
  33. Seki R, Hashimoto T, Tanaka M, et al. Relapse of psychiatric symptoms after discontinuation of antipsychotics in pregnant women with schizophrenia: A retrospective study. Clin Neuropsychopharmacol Ther. 2020;11:61–66. https://doi.org/10.5234/cnpt.11.61
  34. Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: Prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–1824. https://doi.org/10.1176/appi.ajp.2007.06101639
  35. Wesseloo R, Kamperman AM, Munk-Olsen T, et al. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: A systematic review and meta-analysis. Am J Psychiatry. 2016;173(2):117–127. https://doi.org/10.1176/appi.ajp.2015.15010124
  36. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. John Wiley and Sons Inc.: New York, NY; 2018.
  37. Ameyaw EK, Budu E, Sambah F, et al. Prevalence and determinants of unintended pregnancy in sub-Saharan Africa: A multi-country analysis of demographic and health surveys. PLoS One. 2019;14(8):e0220970. https://doi.org/10.1371/journal.pone.0220970
  38. du Toit E, Jordaan E, Niehaus D, et al. Risk factors for unplanned pregnancy in women with mental illness living in a developing country. Arch Womens Ment Health. 2018;21(3):323–331. https://doi.org/10.1007/s00737-017-0797-7
  39. Macfarlane A, Greenhalgh T. Sodium valproate in pregnancy: What are the risks and should we use a shared decision-making approach?. BMC Pregnancy Childbirth. 2018;18(1):200. https://doi.org/10.1186/s12884-018-1842-x
  40. Statistics South Africa. 2018 General household survey. Statistics South Africa: Pretoria; 2020.
  41. Leckman-Westin E, Kealey E, Gupta N, et al. Validation of a claims-based antipsychotic polypharmacy measure. Pharmacoepidemiol Drug Saf. 2014;23(6):628–635. https://doi.org/10.1002/pds.3609
  42. Broeks SC, Thisted Horsdal H, Glejsted Ingstrup K, et al. Psychopharmacological drug utilization patterns in pregnant women with bipolar disorder - A nationwide register-based study. J Affect Disord. 2017;210:158–165. https://doi.org/10.1016/j.jad.2016.12.001
  43. World Medical Association. World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. J Am Med Assoc. 2013;310(20):2191–2194. https://doi.org/10.1001/jama.2013.281053
  44. Knudsen TM, Hansen A V., Garne E, et al. Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy – An epidemiological study using validated EUROCAT data. BMC Pregnancy Childbirth. 2014;14:333. https://doi.org/10.1186/1471-2393-14-333
  45. Margulis A V., Abou-Ali A, Strazzeri MM, et al. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: A propensity-score matched cohort in CPRD. Pharmacoepidemiol Drug Saf. 2013;22(9):942–951. https://doi.org/10.1002/pds.3462
  46. Vasilakis-Scaramozza C, Aschengrau A, Cabral H, et al. Antidepressant use during early pregnancy and the risk of congenital anomalies. Pharmacotherapy. 2013;33(7):693–700. https://doi.org/10.1002/phar.1211
  47. Gentile S. Tricyclic antidepressants in pregnancy and puerperium. Expert Opin Drug Saf. 2014;13(2):207–225. https://doi.org/10.1517/14740338.2014.869582
  48. Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938–946. https://doi.org/10.1001/jamapsychiatry.2016.1520
  49. Bodeń R, Lundgren M, Brandt L, et al. Antipsychotics during pregnancy: Relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69(7):715–721. https://doi.org/10.1001/archgenpsychiatry.2011.1870
  50. Edinoff AN, Sathivadivel N, McNeil SE, et al. Antipsychotic use in pregnancy: Patient mental health challenges, teratogenicity, pregnancy complications, and postnatal risks. Neurol Int. 2022;14(1):62–74. https://doi.org/10.3390/neurolint14010005
  51. Werler MM, Ahrens KA, Bosco JLF, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol. 2011;21(11):842–850. https://doi.org/10.1016/j.annepidem.2011.08.002
  52. World Health Organization (WHO). Statement on the risks associated with use of valproic acid (sodium valproate) in women and girls of childbearing potential [homepage on the Internet]. 2025 [cited 07 August 2025]. Available from: https://www.who.int/news/item/02-05-2023-use-of-valproic-acid-in-women-and-girls-of-childbearing-potential
  53. Ranjith S, Joshi A. Measures to mitigate sodium valproate use in pregnant women with epilepsy. Cureus. 2022;14(10):e30144. https://doi.org/10.7759/cureus.30144
  54. Gasa PS, Tomita A, Juby V, et al. The valproate prescription pattern for female mental healthcare users of reproductive age. S Afr J Psychiatry. 2024;30:2158. https://doi.org/10.4102/sajpsychiatry.v30i0.2158
  55. Sibanyoni AU, Joubert M, Naidu K. Are female bipolar patients of reproductive age aware of the teratogenic risk of sodium valproate? A qualitative study. S Afr J Psychiatry. 2022;28:1719. https://doi.org/10.4102/sajpsychiatry.v28i0.1719
  56. Galvin LJ, Nel YM. Contraceptive use in women with mental illness in Soweto, South Africa. S Afr J Psychiatry. 2024;30:2153. https://doi.org/10.4102/sajpsychiatry.v30i0.2153
  57. Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: A prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–538. https://doi.org/10.1016/S1474-4422(18)30107-8
  58. Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692–1699. https://doi.org/10.1212/WNL.0b013e3182574f39
  59. Bjørk MH, Zoega H, Leinonen MK, et al. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol. 2022;79(7):672–681. https://doi.org/10.1001/jamaneurol.2022.1269
  60. Meador KJ. Risks of fetal exposure to topiramate. New Engl J Med. 2024;390(12):1141–1142. https://doi.org/10.1056/NEJMe2401164
  61. Potorno E, Huybrechts KF, Hernandez-Diaz S. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med. 2017;377(9):893–894. https://doi.org/10.1056/NEJMc1708919
  62. Ogawa Y, Takeshima N, Furukawa TA. Maternal exposure to benzodiazepine and risk of preterm birth and low birth weight: A case-control study using a claims database in Japan. Asia-Pacific Psychiatry. 2018;10(3):e12309. https://doi.org/10.1111/appy.12309
  63. Galbally M, Frayne J, Watson SJ, et al. Psychopharmacological prescribing practices in pregnancy for women with severe mental illness: A multicentre study. Eur Neuropsychopharmacol. 2019;29(1):57–65. https://doi.org/10.1016/j.euroneuro.2018.11.1103
  64. Preskorn SH. Drug-drug interactions (DDIs) in psychiatric practice, Part 9: Interactions mediated by drug-metabolizing cytochrome P450 enzymes. J Psychiatr Pract. 2020;26(2):126–134. https://doi.org/10.1097/PRA.0000000000000458
  65. Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Food and Drug Administration: Silver Spring, MD; 2014.
  66. Freeman MP, Farchione T, Yao L, et al. Psychiatric medications and reproductive safety: Scientific and clinical perspectives pertaining to the US FDA pregnancy and lactation labeling rule. J Clin Psychiatry. 2018;79(4):18ah38120. https://doi.org/10.4088/JCP.18ah38120
  67. Farmer C. Psychotropic medication prescribing patterns during pregnancy in two South African Maternal Mental Health clinics [MMed thesis]. Stellenbosch: Stellenbosch University; 2023.

 

Crossref Citations

1. Service use and obstetric outcomes in pregnant women attending a Women’s Mental Health Clinic
Menasia Patterson, Deidré Mason, Juané Voges, Kerry-Ann Louw
Journal of the Colleges of Medicine of South Africa  vol: 4  issue: 1  year: 2026  
doi: 10.4102/JCMSA.v4i1.326